LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple Turns 50: From Garage Startup to AI Crossroads 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SAN DIEGO, Aug. 01, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended June 30, 2017, before the opening of trading on Tuesday, August 8, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Tuesday, August 8. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-4771 (preferred), or (888) 417-2254 (toll-free), and reference confirmation code 6860083. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 6860083. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Andrew Hopkins (858) 646-1127 Website: www.vical.com
